Health Care & Hospital Law,
Government,
Civil Litigation
Oct. 22, 2020
Purdue deal puts government in opioid business, critics say
Under terms of the tentative deal, Purdue Pharma -- best known for its most drug OxyContin -- will cease to operate in its current form after the company emerges from bankruptcy and will instead operate as a public benefit company run by a trust.
The U.S. Department of Justice's settlement of its criminal and civil investigation of Purdue Pharma LP and the family that long ran it will put the government in the opioid business, critics say.
Under terms of the tentative deal, Purdue Pharma -- best known for its most drug OxyContin -- will cease to operate in its current form after the company emerges from bankruptcy and will instead operate as a public benefit company run by a ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In